Código QR (código de barras bidimensional)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells. Idelalisib is a highly selective inhibi...

ver descrição completa

Na minha lista:
Principais autores: Lisa Rohrbacher, Bettina Brauchle, Ana Ogrinc Wagner, Michael von Bergwelt-Baildon, Veit L. Bücklein, Marion Subklewe
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021-03-01
coleção:Frontiers in Immunology
Assuntos:
cancer immunotherapy
chronic lymphocytic leukemia
idelalisib
immune effector cells
PI3K inhibition
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2021.608625/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados